8/4/2019 Clinical Protocol by Ekta
1/24
Clinical Research Protocol
Prepared by: Ekta A. SharmaMpharm (QA)1st SEMRoll no. 10
Guided by: Mrs.H.D.SolankiDept. of pharmacology
Dharmaj Degree Pharmacy College, Dharmaj
8/4/2019 Clinical Protocol by Ekta
2/24
Introduction:
The study of protocol is the blueprint thatall researches will follow. A study protocol is adocument that describes in details, the plan for
purpose & function of the study as well as howto carry it out.
8/4/2019 Clinical Protocol by Ekta
3/24
Appendix X
CONTENTS OF THE PROPOSED PROTOCOL FORCONDUCTING CLINICAL TRIALS
Title Page: Full title of the clinical study.
Protocol / Studynumber, and protocolversionnumber with date.
Complete name and address of the Sponsor andcontract research organization.
List of the Investigators, their site locations.
Names ofclinical laboratories .
8/4/2019 Clinical Protocol by Ekta
4/24
Table of Contents:
A complete Table of Contents including a list of allAppendices.
Page number or other locating information of eachsection, including summarytables , figures, andgraphs.
Background and Introduction:a. Preclinical experience
b. Clinical experience
8/4/2019 Clinical Protocol by Ekta
5/24
Previous clinical should be reviewed here .
If this is an entirely new indication, how thisdrug was considered for this should bediscussed.
Relevant information regardingpharmacological, toxicological and otherbiological properties of thedrug/biologic/medical device, and previous
efficacy and safety experience should bedescribed.
8/4/2019 Clinical Protocol by Ekta
6/24
Study Rationale:
It describes the background information relevantto the study design and protocol methodology.
The reasons for performing this study in theparticular population included should beprovided.
StudyObjective (primary as well as secondary)
and their logical relation to the study design.
8/4/2019 Clinical Protocol by Ekta
7/24
Study Design:
Overview of the Study Design
Flow chart of the study
A brief description of the methods & procedures
Study Population:
The number of Subjects required in the study atthe investigative site are mentioned.
8/4/2019 Clinical Protocol by Ekta
8/24
Subject Eligibility:
a. Inclusion Criteria
b. Exclusion Criteria
Study Assessments:Plan, procedures and methods to be described in
detail.
8/4/2019 Clinical Protocol by Ekta
9/24
Study Conduct: Types of study activities like medical history, type
of physical examination, blood or urine testing,electrocardiogram (ECG), diagnostic testing suchas pulmonary function tests.
Dispensation and retrieval of medication, adverseevent review, etc.
Each visit should be described separately as Visit
1, Visit 2, etc. Discontinued Subject: Describes the
circumstances for Subjectwithdrawal.
8/4/2019 Clinical Protocol by Ekta
10/24
Describes conditions where the study will beterminated for non-compliance with the protocol.
Study Treatment: Describe Dosing schedule , administration of
placebos.
If applicable, concomitant drug, their doses,frequency, and duration of concomitanttreatment should be stated.
Study drug supplies and administration.
Details of the product stability& storagerequirements should be provided.
8/4/2019 Clinical Protocol by Ekta
11/24
Dose modification for study drug toxicity
Possible drug interactions Concomitant therapy: The drugs that are
permitted during the study and the conditionsunder which they may be used are detailed here.
If anywashout periods for prohibitedmedications are needed prior to study, theseshould be described here.
Blinding procedures: A detailed description ofthe blinding procedure is given.
8/4/2019 Clinical Protocol by Ekta
12/24
Unblinding procedures:
If the study is blinded, the circumstances inwhich unblinding may be done and the
mechanism to be used for unblinding should begiven.
Adverse Events:
Description of expected adverse events should begiven.
Procedures used to evaluate an adverse eventshould be described.
8/4/2019 Clinical Protocol by Ekta
13/24
Ethical Considerations:
Risk / benefit assessment Ethics Committee review and communications
Statement ofSubject confidentialityincludingownership of data and coding procedures
Study Monitoring and Supervision: A description of studymonitoring policies and
procedures should be provided.
8/4/2019 Clinical Protocol by Ekta
14/24
Case Record Form (CRF) completionrequirements.
Investigator study files, including what needs tobe stored following study completion should be
described.Investigational Product
Management:
product description and packaging The precise dosing required during the study
8/4/2019 Clinical Protocol by Ekta
15/24
Method ofpackaging, labeling
Storage conditions for study substances. Investigational product accountability: Describe
instructions for the receipt, storage, dispensation,and return of the investigational products
Describe policy and procedure for handling unusedinvestigational products.
8/4/2019 Clinical Protocol by Ekta
16/24
Data Analysis:
Details of the statistical approach includingsample size, assumptions , efficacy endpoint andsafety endpoints.
Statistical analysis: Describe the statistical teststo be used, and the methods used for missingdata, non-compliance, and Subjectwithdrawals.
8/4/2019 Clinical Protocol by Ekta
17/24
Undertaking by the Investigator Checking ofCRF
Checking of all the parameters related to the study design,methodology
Checking of volunteer assessment form etc.
Appendices: Copies of the informed consent documents (patient
information sheet, informed consent form etc.)
CRF and other data collection forms A summary of relevant pre-clinical safety information
Any other documents referenced in the clinicalprotocol.
8/4/2019 Clinical Protocol by Ekta
18/24
Defining the study design for the
protocol: Protocols may outline one of several different
types of study designs, some which are describedbelow, that investigators may follow:
a) Case Study: This type of study relies on aliterature review or uses a physicians clinical casesto introduce a clinical abnormality, usually
something rare, new, or something that presents inan unusual way.
8/4/2019 Clinical Protocol by Ekta
19/24
b) Case-Control Study:This study compares
the number of people who had a potential riskfactor in the case group (thosewith the disease)with those who had the same potential risk factorin the control group (thosewithout the disease).
c) Cohort Study:This type of study comparesrisk factors shared between the case group and thecontrol group. This type of study can be prospectiveor retrospective.
8/4/2019 Clinical Protocol by Ekta
20/24
d) Randomized Controlled Trial (RCT):
In this type of study, participants are randomlyassigned, into the control group or theinvestigational group. The control group receivesthe approved treatment; the investigational group
receives the treatment being studied.
e) Blind Studies: participants do not knowwhich group they are randomly assigned to.
8/4/2019 Clinical Protocol by Ekta
21/24
f) Double-blind studies: means that neither the
study personnel who interact with participants, northe participants know who is assigned to whichgroup.
- Another variation of this design is called a
double-dummy study, meaning participantsreceive a mixture of active and inactive product.These study designs are meant to eliminatepossible bias by the participants.
8/4/2019 Clinical Protocol by Ekta
22/24
g) Meta-analysis: This type of study involves
analysis ofmultiple similar studies that areperformed according to a protocol that outlines themethodology to be used.
8/4/2019 Clinical Protocol by Ekta
23/24
References: http://google2.fda.gov/search?q=helsinki+declara
tion&client=FDAgov&site=FDAgov&lr=&proxystylesheet=FDAgov&output=xml_no_dtd&getfields=*
http://www.wma.net/en/30publications/10policies/b3/index.html
http://google2.fda.gov/search?q=helsinki+declaration&client=FDAgov&site=FDAgov&lr=&proxystylesheet=FDAgov&output=xml_no_dtd&getfields=*http://google2.fda.gov/search?q=helsinki+declaration&client=FDAgov&site=FDAgov&lr=&proxystylesheet=FDAgov&output=xml_no_dtd&getfields=*http://google2.fda.gov/search?q=helsinki+declaration&client=FDAgov&site=FDAgov&lr=&proxystylesheet=FDAgov&output=xml_no_dtd&getfields=*http://google2.fda.gov/search?q=helsinki+declaration&client=FDAgov&site=FDAgov&lr=&proxystylesheet=FDAgov&output=xml_no_dtd&getfields=*http://google2.fda.gov/search?q=helsinki+declaration&client=FDAgov&site=FDAgov&lr=&proxystylesheet=FDAgov&output=xml_no_dtd&getfields=*http://google2.fda.gov/search?q=helsinki+declaration&client=FDAgov&site=FDAgov&lr=&proxystylesheet=FDAgov&output=xml_no_dtd&getfields=*8/4/2019 Clinical Protocol by Ekta
24/24
ThankYou